Gilead Presents Results of Veklury (remdesivir) in Multiple Studies for COVID-19 at ECCMIC 2022
- The RWE from 850,000 patients provides clinical insights on Veklury for COVID-19 which showed that 50% received Veklury with other therapies, reduction in median hospital LOS & ICU use with the greatest benefit in IMV/ ECMO & high-flow oxygen/NIV, overall mortality rates remained stable
- The posthoc analysis from a P-III (PINETREE) study showed a 90% & 81% reduction in risk of hospitalization within 5days of symptoms & after 5days, respectively
- The new analysis is based on the prior analysis which showed an 87% reduction in risk for composite 1EPs of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% with Veklury vs PBO (5.3%) with no deaths. The company presented 2 additional studies in clinical & RWE programs
Ref: Gilead | Image: Gilead
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.